Use of compounded hormone therapy in the United States: Report of the North American menopause society survey

Menopause

Volumn 22, Issue 12, 2015, Pages 1276-1284

  Gass, Margery L S ^a   Stuenkel, Cynthia A ^b   Utian, Wulf H ^a   Croix, Andrea La ^c   Liu, James H ^d   Shifren, Jan L ^e  

^a North American Menopause Society   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bioidentical; Compounded hormone therapy; FDA; Testosterone

Indexed keywords

ANDROSTENEDIONE; CHORIONIC GONADOTROPIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; GROWTH HORMONE; PRASTERONE; PROGESTERONE; TESTOSTERONE;

ACNE; ADULT; AGE; AGED; AGING; BEHAVIOR DISORDER; BREAST CANCER; BREAST TENDERNESS; CEREBROVASCULAR ACCIDENT; COMPOUNDED HORMONE THERAPY; CREAM; DEPRESSION; DRUG INDICATION; DRUG PELLET; EDUCATIONAL STATUS; ENDOMETRIUM CANCER; FEMALE; GEL; GEOGRAPHIC DISTRIBUTION; GYNECOLOGIC DISEASE; GYNECOLOGIST; HAIR DISEASE; HEALTH CARE SURVEY; HEART INFARCTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYSTERECTOMY; INCOME; INTERNET; IRRITABILITY; LOTION; LOZENGE; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MEMORY; MENTAL CONCENTRATION; MIDDLE AGED; MOOD; MUSCLE MASS; OSTEOPOROSIS; OVARIECTOMY; PILL; POSTMENOPAUSE; PRESCRIPTION; QUALITY OF LIFE; RACE; REVIEW; SALIVA ANALYSIS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SLEEP DISORDER; TABLET; TRANSDERMAL PATCH; UNITED STATES; UTERUS CANCER; VAGINA BLEEDING; VAGINA RING; VAGINAL DRYNESS; VASOMOTOR DISORDER; WEIGHT REDUCTION; WELLBEING; ADVERSE EFFECTS; ENDOMETRIAL NEOPLASMS; ESTROGEN THERAPY; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; MENOPAUSE; PROCEDURES; QUESTIONNAIRE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; EDUCATIONAL STATUS; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCOME; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TESTOSTERONE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84952628898     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000553     Document Type: Review

References (37)

1. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Womens Health Initiative. Menopause 2012;19:616-621.
2. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 2011;18:385-392.
3. MacLennan AH, Gill TK, Broadbent JL, Taylor AW. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009;12:122-130.
4. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
6. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Womens Health Initiative randomized trials. JAMA 2013;310:1353-1368.
7. Merriam-Webster. Definition of bioidentical. Available at: http://www.merriam-webster.com/dictionary/bioidentical. Accessed May 15, 2015.
8. Bhavnani BR, Stanczyk FZ. Misconception and concerns about bioidentical hormones used for custom-compounded hormone therapy. J Clin Endocrinol Metab 2012;97:756-759.
9. US Food and Drug Administration. Bio-Identicals: Sorting Myths from Facts. April 8, 2008. FDA Consumer Health Information. Available at: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM049312.pdf. Accessed March 8, 2015.
10. Sellers S, Utian WH. Pharmacy compounding primer for physicians. Prescriber beware. Drugs 2012;72:2043-2050.
11. State of Tennessee Office of the Attorney General and Reporter. State of Tennessee v HRC Medical Centers. First amended complaint for temporary and permanent injunction, judicial corporate dissolution, and other relief. Case No. 12C4047. Available at: http://attorneyge neral.tn.gov/cases/hrc/hrcamendedcomplaint.pdf. Accessed July 11, 2015.
12. Smith RM, Schaefer MK, Kainer MA, et al. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med 2013;369:1598-1609.
13. FDA takes action against compounded menopause hormone therapy drugs [press release]. January 9, 2008. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116832.htm. Accessed June 18, 2015.
14. Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause 2015;22:926-936.
15. Mirkin S, Krasssan M, Bernick B, Constantine GD. Usage of FDAapproved and compounded menopausal hormone therapy in the USA following the WHI study. Menopause 2014;21:1357.
16. MacLennan AH. Evidence-based review of therapies at the menopause. Int J Evid Based Healthc 2009;7:112-123.
17. Yuksel N, Brochu L, Malik B, Bayot A. Promotion and marketing of bioidentical hormone therapy on the internet: a content analysis of websites. Menopause 2014;21:1329.
18. Bioidentical Hormone Doctors. Bioidentical Hormones-Oprah Talks. October 9, 2012. Available at: https://www.youtube.com/watch? v=7kEffjzrlLQ. Accessed May 22, 2015.
19. Oprah.com. To: Oprah Winfrey; Subject: Hormones. What I know for sure. Available at: http://www.oprah.com/article/omagazine/200902-omag-oprah-for-sure. Accessed May 22, 2015.
20. Somers S. Ageless: The Naked Truth About Bioidentical Hormones. New York: Crown Publishing Group, Random House; 2006.
21. Cobin RH, Petak SM, Bledsoe MB. American Association of Clinical Endocrinologists (AACE) Reproductive Medicine Committee position statement on bioidentical hormones. July 15, 2007. Available at: https://www.aace.com/files/position-statements/aacebhstatement071507.pdf. Accessed June 16, 2015.
22. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; American Society for Reproductive Medicine Practice Committee. Compounded bioidentical menopausal hormone therapy. Fertil Steril 2012;98:308-312.
23. American Medical Association, FDA Oversight of Bioidentical Hormone (BH) Preparations. Resolution 706 in AMA House of Delegates Meeting. 2006: Las Vegas, NV.
24. The Endocrine Society. Position Statement: Bioidentical Hormones. October 2006. Available at: https://www.endocrine.org/advocacy-Andoutreach/position-statements. Accessed August 5, 2015.
25. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-271.
26. Pinkerton JV. What are the concerns about custom-compounded bioidentical hormone therapy? Menopause 2014;21:1298-1300.
27. Moyer VA; US Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
28. McBane SE, Borgelt LM, Barnes KN, Westberg SM, Lodise NM, Stassinos M. Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Womens Health Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2014;34:410-423.
29. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop10: addressing the unfinished agenda of staging reproductive aging. Menopause 2012;19:387-395.
30. United States Census Bureau. Annual population estimates: US population by year. Available at: https://www.census.gov/popclock/data-tables. php?component=growth. Accessed July 4, 2015.
31. Iftikhar S, Shuster LT, Johnson RE, Jenkins SM, Wahner-Roedler DL. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchmt) 2011;20:559-565.
32. Rosenthal MS. The Wiley Protocol: an analysis of ethical issues. Menopause 2008;15:1014-1022.
33. Fishman JR, Flatt MA, Settersten RA Jr. Bioidentical hormones, menopausal women, and the lure of the natural in U.S. anti-Aging medicine. Soc Sci Med 2015;132:79-87.
34. US Food and Drug Administration. Report: limited FDA survey of compounded drug products. June 18, 2009. Available at: http://www.fda.-gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm. Accessed June 18, 2015.
35. Davis R, Batur P, Thacker HL. Risks and effectiveness of compounded bioidentical hormone therapy: a case series. JWomensHealth 2014;23:642-648.
36. Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with bioidentical hormone replacement therapy. Med J Aust 2007;187:244-245.
37. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13-18.